VEGF and angiogenesis in acute and chronic MOG(35-55) peptide induced EAE

Journal of Neuroimmunology

Volumn 209, Issue 1-2, 2009, Pages 6-15

  Roscoe, W A ^a,b   Welsh, M E ^a,b   Carter, D E ^a,b   Karlik, S J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Alanyl aminopeptidase; Angiogenesis; Caspase 8; EAE; Hif1a; Laminin; MMP 19; MS; Multiple sclerosis; Plasminogen activator inhibitor; Remyelination; SU5416; Thrombospondin; VEGF

Indexed keywords

ANGIOGENIC FACTOR; CASPASE 8; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAMININ; MATRIX METALLOPROTEINASE 19; MICROSOMAL AMINOPEPTIDASE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROGLIAL GLYCOPROTEIN [35-55]; PLASMINOGEN ACTIVATOR INHIBITOR; SEMAXANIB; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACUTE BRAIN DISEASE; ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; C57BL 6 MOUSE; CELL INFILTRATION; CHRONIC BRAIN DISEASE; CHRONIC DISEASE; CONTROL GROUP; CONTROLLED STUDY; DEMYELINATION; FEMALE; GENE EXPRESSION REGULATION; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA TRANSCRIPTION; SPINAL CORD TRANSSECTION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; INDOLES; LAMININ; MICE; MICE, INBRED C57BL; MYELIN SHEATH; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PYRROLES; RNA, MESSENGER; SPINAL CORD; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WALLERIAN DEGENERATION;

EID: 64549147068     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.01.009     Document Type: Article

References (52)

1. Ahnert P., and Kirsten H. Association of ITGAV supports a role of angiogenesis in rheumatoid arthritis. Arthritis Res. Ther. 9 (2007) 108
2. Airley R.E., and Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53 (2007) 233-256
3. Albo D., Rothman V.L., Roberts D.D., and Tuszynski G.P. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br. J. Cancer 83 (2000) 298-306
4. Allen I.V., Glover G., and Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol. Suppl. 7 (1981) 176-178
5. Bauerle T., Hilbig H., Bartling S., Kiessling F., Kersten A., Schmitt-Graff A., Kauczor H.U., Delorme S., and Berger M.R. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 10 (2008) 511-520
6. Bouerat L., Fensholdt J., Liang X., Havez S., Nielsen S.F., Hansen J.R., Bolvig S., and Andersson C. Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis. J. Med. Chem. 48 (2005) 5412-5414
7. Braun, M., Flucke, U., Debald, M., Walgenbach-Bruenagel, G., Walgenbach, K.J., Holler, T., Polcher, M., Wolfgarten, M., Sauerwald, A., Keyver-Paik, M., Kuhr, M., Buttner, R., Kuhn, W., (2007) Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res. Treat.
8. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002) 1297-1308
9. Carvalho J.F., Blank M., and Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 27 (2007) 246-256
10. Colombo B.M., Cacciapaglia F., Puntoni M., Murdaca G., Rossi E., Rodriguez G., Nobili F., Pisciotta L., Bertolini S., Moccetti T., Dentali F., Steidl L., Ciprandi G., Afeltra A., Indiveri F., and Puppo F. Traditional and nontraditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun. Rev. (2008) Oct 28 [Electronic publication ahead of print]
11. Costa C., Incio J., and Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis 10 (2007) 149-166
12. Huang W., Wu Y.L., Zhong J., Jiang F.X., Tian X.L., and Yu L.F. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig. Dis. Sci. 53 (2008) 1206-1210
13. Jang Y.J., Kim D.S., Jeon O.H., and Kim D.S. Saxatilin suppresses tumor-induced angiogenesis by regulating VEGF expression in NCI-H460 human lung cancer cells. J. Biochem. Mol. Biol. 40 (2007) 439-443
14. Jarvenpaa J., Vuoristo J.T., Savolainen E.R., Ukkola O., Vaskivuo T., and Ryynanen M. Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction. Gynecol. Endocrinol. 23 (2007) 351-355
15. Kang Y.A., Shin H.C., Yoo J.Y., Kim J.H., Kim J.S., and Yun C.O. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol. Ther. 16 (2008) 1033-1040
16. Kanwar J.R. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem. 12 (2005) 2947-2962
17. Kawaguchi H., El-Naggar A.K., Papadimitrakopoulou V., Ren H., Fan Y.H., Feng L., Lee J.J., Kim E., Hong W.K., Lippman S.M., and Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J. Clin. Oncol. 26 (2008) 354-360
18. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129 2 (2008) (Jul 14), 107-116 [Electronic publication ahead of print, 2008 Mar 14]
19. Kirk S., Frank J.A., and Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J. Neurol. Sci. 217 (2004) 125-130
20. Kirk S.L., and Karlik S.J. VEGF and vascular changes in chronic neuroinflammation. J. Autoimmun. 21 (2003) 353-363
21. Ko A.H., Dito E., Schillinger B., Venook A.P., Xu Z., Bergsland E.K., Wong D., Scott J., Hwang J., and Tempero M.A. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. Invest. New Drugs 26 5 (2008) (Oct), 463-471 [Electronic ahead of publication, 2008 Apr 1]
22. Koch A.E., and Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 9 Suppl. 2 (2007) S3
23. Krum J.M., Mani N., and Rosenstein J.M. Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Exp. Neurol. 212 (2008) 108-117
24. Landau B.J., Kwaan H.C., Verrusio E.N., and Brem S.S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 54 (1994) 1105-1108
25. Lu C., Pelech S., Zhang H., Bond J., Spach K., Noubade R., Blankenhorn E.P., and Teuscher C. Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. J. Neurosci. Res. 86 (2008) 2624-2640
26. Lu Y., Zhang J., and Qian J. The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother. Radiopharm. 23 (2008) 222-228
27. Macchi G. The pathology of the blood vessels in multiple sclerosis. J. Neuropathol. Exp. Neurol. 13 (1954) 378-384
28. + T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol. Res. 28 (2006) 256-261
29. Mojzis J., Varinska L., Mojzisova G., Kostova I., and Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol. Res. 57 (2008) 259-265
30. Muroski M.E., Roycik M.D., Newcomer R.G., Van den Steen P.E., Opdenakker G., Monroe H.R., Sahab Z.J., and Sang Q.X. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9 (2008) 34-46
31. Noonan D.M., De Lerma B.A., Vannini N., Mortara L., and Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27 (2008) 31-40
32. Piraino P.S., Yednock T.A., Freedman S.B., Messersmith E.K., Pleiss M.A., Vandevert C., Thorsett E.D., and Karlik S.J. Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J. Neuroimmunol. 131 (2002) 147-159
33. Poser C.M. Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol. 71 (1986) 1-10
34. Proescholdt M.A., Jacobson S., Tresser N., Oldfield E.H., and Merrill M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J. Neuropathol. Exp. Neurol. 61 (2002) 914-925
35. Rigau V., Morin M., Rousset M.C., de B.F., Lebrun A., Coubes P., Picot M.C., Baldy-Moulinier M., Bockaert J., Crespel A., and Lerner-Natoli M. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 130 (2007) 1942-1956
36. Roscoe W.A., Messersmith E., Meyer-Franke A., Wipke B., and Karlik S.J. Connexin 43 gap junction proteins are up-regulated in remyelinating spinal cord. J. Neurosci. Res. 85 (2007) 945-953
37. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8 (2002) 586-595
38. Sanchez A.J., Puerta C., Ballester S., Gonzalez P., Arriaga A., and Garcia-Merino A. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168 (2005) 13-20
39. Secord A.A., Darcy K.M., Hutson A., Lee P.S., Havrilesky L.J., Grace L.A., and Berchuck A. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 (2007) 221-232
40. Sedlacek R., Mauch S., Kolb B., Schatzlein C., Eibel H., Peter H.H., Schmitt J., and Krawinkel U. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 198 (1998) 408-423
41. Steinman L., and Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26 (2005) 565-571
42. St Louis J., Uniyal S., Xu L., Chan E., Singh B., Chan B.M., and Strejan G.H. Tolerance induction by acylated peptides: suppression of EAE in the mouse with palmitoylated PLP peptides. J. Neuroimmunol. 115 1-2 (2001) (Apr 2), 79-90
43. Tamargo R.J., Bok R.A., and Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51 (1991) 672-675
44. Tham E., Gielen A.W., Khademi M., Martin C., and Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand. J. Immunol. 64 (2006) 609-622
45. Theoharides T.C., and Konstantinidou A.D. Corticotropin-releasing hormone and the blood-brain-barrier. Front. Biosci. 12 (2007) 1615-1628
46. Wang L., Chen W., Xie X., He Y., and Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp. Oncol. 30 (2008) 42-51
47. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin. Diagn. Pathol. 10 4 (1993) (Nov.), 302-313. Review
48. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324 1 (1991) (Jan. 3), 1-8
49. Yao J.S., Chen Y., Zhai W., Xu K., Young W.L., and Yang G.Y. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ. Res. 95 (2004) 364-371
50. Yong V.W., Zabad R.K., Agrawal S., Goncalves D.A., and Metz L.M. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci. 259 (2007) 79-84
51. Zabad R.K., Metz L.M., Todoruk T.R., Zhang Y., Mitchell J.R., Yeung M., Patry D.G., Bell R.B., and Yong V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler. 13 (2007) 517-526
52. Zhu Y., Shwe Y., Du R., Chen Y., Shen F.X., Young W.L., and Yang G.Y. Effects of angiopoietin-1 on vascular endothelial growth factor-induced angiogenesis in the mouse brain. Acta Neurochir. Suppl. 96 (2006) 438-443